

# SECURITIES & EXCHANGE COMMISSION EDGAR FILING

## Cord Blood America, Inc.

**Form: 8-K**

**Date Filed: 2017-08-11**

Corporate Issuer CIK: 1289496

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2017

**CORD BLOOD AMERICA, INC.**

(Exact name of registrant as specified in its charter)

**Florida**  
(State or Other Jurisdiction  
of Incorporation)

**000-50746**  
(Commission  
File Number)

**90-0613888**  
(I.R.S. Employer  
Identification No.)

**1857 Helm Drive, Las Vegas, NV 89119**  
(Address of Principal Executive Office) (Zip Code)

**(702) 914-7250**  
(Registrant's telephone number, including area code)

---

**Copies to:**

**Anthony Snow**  
**1857 Helm Drive, Las Vegas, NV 89119**  
**Phone: (702) 914-7250**  
**Fax: (702) 914-7251**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On August 11, 2017, Cord Blood America, Inc. (the "Company") issued the Press Release attached as Exhibit 99.1 to this Current Report. The Press Release provides details related to the Company's financial results and earnings for the three month period ended June 30, 2017. The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The following Exhibits are furnished herewith:

| <u>Exhibit No.</u>   | <u>Description</u>                  |
|----------------------|-------------------------------------|
| <a href="#">99.1</a> | Press Release dated August 11, 2017 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORD BLOOD AMERICA, INC.**

Date: August 11, 2017

By: /s/ Anthony Snow

\_\_\_\_\_  
Anthony Snow

Interim President and Corporate Secretary

---

**Cord Blood America Reports 2017 Second Quarter Results**

August 11, 2017 - Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the second quarter ended June 30, 2017.

**Second Quarter Highlights Include:**

- Total revenue for the second quarter was \$0.75 million, a decrease of 5.9% from total revenue of \$0.79 million for the second quarter 2016.
- Recurring storage revenue for the second quarter 2017 was \$0.66 million, a decrease of 4.4% from recurring storage revenue of \$0.69 million for the second quarter 2016.
- EBITDA for the second quarter 2017 was \$0.20 million, an increase of 151.9% from EBITDA of \$0.08 million for the second quarter 2016.

**Results of Operations for the Three-Months Ended June 30, 2017**

For the three months ended June 30, 2017, total revenue was \$0.75 million, a decrease of \$0.04 million or 5.9% from \$0.79 million in second quarter 2016. Of the \$0.04 million decrease, approximately \$0.03 million was attributable to the reduction in storage and processing revenue from a previously terminated agreement with a third party. The discontinuation of storage revenue from the third party accounted for the decline in the Company's recurring storage revenue in the quarter.

Gross Profit for the three months ended June 30, 2017 was \$0.57 million, a decrease of \$0.02 million or 3.6% from \$0.59 million in second quarter 2016. Of the \$0.02 million decrease, approximately \$0.03 million was attributable to the reduction in storage and processing revenue from the third party, offset by reductions made by the Company in cost of goods sold.

Gross Margin for the three months ended June 30, 2017 was 76.4% compared to 74.6% in second quarter 2016. Gross margin increased due to reductions made by the Company in cost of goods sold.

Net Income for the three months ended June 30, 2017 was \$0.15 million compared to a loss of \$0.03 million in second quarter 2016 .

EBITDA for the three months ended June 30, 2017 was \$0.20 million, an increase of \$0.12 million or 151.9% from \$0.08 in second quarter 2016 despite the reduction in revenue as the Company has reduced costs.

David Sandberg, Chairman of the Board, commented, "On July 7<sup>th</sup>, the Company made its final payment to Tonaquint which constituted payment in full of the original \$2.5 million principal obligation and associated interest. The business is performing in line with our previous guidance and has net cash of approximately \$0.73 mm while continuing to generate consistent cash flow. The board continues to evaluate ways to optimize shareholder value."

---

## Non-GAAP Measures

In addition to the GAAP financial measures set forth in this press release, the Company has included the non-GAAP measurement EBITDA which presents operating results on a basis adjusted for depreciation, amortization, interest expense and taxes. The Company uses this non-GAAP measure as a key performance measure for the purpose of evaluating performance internally. The Company also believes this non-GAAP measure provides our investors with useful information regarding our operating results. This non-GAAP measure is not intended to replace the presentation of our financial results in accordance with GAAP. Use of the term EBITDA may differ from similar measures reported by other companies.  
About Cord Blood America, Inc.

Cord Blood America, Inc. is the parent company of CorCell Companies, Inc. which, along with Cord Blood America, Inc., facilitates umbilical cord blood and cord tissue stem cell processing and storage for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: <http://www.cordblood-america.com/> for investor information and <http://www.corcell.com/> for customer information.

## Forward-Looking Statements

Some statements made in this press release are forward-looking statements. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Investor Contact:  
Anthony Snow  
[asnow@cordblood-america.com](mailto:asnow@cordblood-america.com)

---